ContraFect to present data on staph treatment candidate at ICAAC/ICC
The company will be sharing preclinical data from the CF-301 candidate, a bacteriophage that is in the first phase of development and has shown activity against staph infections without targeting naturally growing bacteria within the human body.
In animal models, when combined with standard antibiotics, CF-301 was successful in increasing survivability compared to antibiotics alone or by itself. ContraFect said that due to a different mechanism that targets a vital portion of the bacteria, antibiotic resistance would be less likely.
The poster presentation will be at noon Friday in Exhibit Hall F at the San Diego Convention Center.
The ICAAC/ICC is a conference that features the latest in biological technology. Presenters consist of leading companies and researchers in fields relating to infectious diseases, pharmaceuticals and pathogen prevention and control. Approximately 10,000 individuals gather and share their findings in research.
ContraFect is focused in the development and research of protein and antibody products to address diseases that are considered to be life-threatening and those with resistance to current treatments.